Pub Date : 2024-01-01Epub Date: 2023-12-08DOI: 10.26502/jcsct.5079218
Yunong Xia, Alexander L Ling, Weijie Zhang, Adam Lee, Mei-Chi Su, Robert F Gruener, Sampreeti Jena, Yingbo Huang, Siddhika Pareek, Yuting Shan, R Stephanie Huang
We recently reported a computational method (IDACombo) designed to predict the efficacy of cancer drug combinations using monotherapy response data and the assumptions of independent drug action. Given the strong agreement between IDACombo predictions and measured drug combination efficacy in vitro and in clinical trials, we believe IDACombo can be of immediate use to researchers who are working to develop novel drug combinations. While we previously released our method as an R package, we have now created an R Shiny application to allow researchers without programming experience to easily utilize this method. The app provides a graphical interface which enables users to easily generate efficacy predictions with IDACombo using provided data from several high-throughput cell line screens or using custom, user-provided data.
我们最近报告了一种计算方法（IDACombo），旨在利用单药治疗反应数据和独立药物作用假设预测抗癌药物组合的疗效。鉴于 IDACombo 预测结果与体外和临床试验中测得的联合用药疗效非常吻合，我们相信 IDACombo 可以立即为致力于开发新型联合用药的研究人员所用。我们以前曾以 R 软件包的形式发布过我们的方法，现在我们创建了一个 R Shiny 应用程序，让没有编程经验的研究人员也能轻松使用这种方法。该应用程序提供了一个图形界面，用户可以使用从多个高通量细胞系筛选中提供的数据或用户提供的自定义数据，通过 IDACombo 轻松生成药效预测。
{"title":"A Web Application for Predicting Drug Combination Efficacy Using Monotherapy Data and IDACombo.","authors":"Yunong Xia, Alexander L Ling, Weijie Zhang, Adam Lee, Mei-Chi Su, Robert F Gruener, Sampreeti Jena, Yingbo Huang, Siddhika Pareek, Yuting Shan, R Stephanie Huang","doi":"10.26502/jcsct.5079218","DOIUrl":"10.26502/jcsct.5079218","url":null,"abstract":"<p><p>We recently reported a computational method (IDACombo) designed to predict the efficacy of cancer drug combinations using monotherapy response data and the assumptions of independent drug action. Given the strong agreement between IDACombo predictions and measured drug combination efficacy in vitro and in clinical trials, we believe IDACombo can be of immediate use to researchers who are working to develop novel drug combinations. While we previously released our method as an R package, we have now created an R Shiny application to allow researchers without programming experience to easily utilize this method. The app provides a graphical interface which enables users to easily generate efficacy predictions with IDACombo using provided data from several high-throughput cell line screens or using custom, user-provided data.</p>","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"7 4","pages":"253-258"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139725201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-08-19DOI: 10.26502/jcsct.5079249
Jeremy Pan, Tony Eskandar, Zubair Ahmed, Devendra K Agrawal
Glioblastoma (GBM) is one of the most aggressive forms of brain cancer that presents with a median survival rate of 14-30 months and along with a discouraging five-year survival rate of 4-5%. Standard treatment of newly diagnosed GBM, also known as the Stupp protocol, includes a maximally safe surgical resection followed by radiation and chemotherapy. Despite these treatment regimens, recurrence is almost inevitable, emphasizing the need for new therapies to combat the aggressive nature of GBMs. Tumor Treating Fields (TTFs) are a relatively new application to the treatment of GBMs, and results have been promising with both progression-free survival and overall survival when TTFs have been used in combination with temozolomide. This article critically reviews the biophysical and biological mechanisms of TTFs, their clinical efficacy, and discusses the results in clinical trials, including EF-11 and EF-14. Both trials have demonstrated that TTFs can enhance progression free survival and overall survival without compromising quality of life or causing severe adverse effects. Despite the high cost associated with TTFs and the need for further analysis to determine the most effective ways to integrate TTFs into GBM treatments, TTFs represent a significant advancement in GBM therapy and offer hope for improved patient prognosis.
{"title":"Biophysical and Biological Mechanisms of Tumor Treating Fields in Glioblastoma.","authors":"Jeremy Pan, Tony Eskandar, Zubair Ahmed, Devendra K Agrawal","doi":"10.26502/jcsct.5079249","DOIUrl":"10.26502/jcsct.5079249","url":null,"abstract":"<p><p>Glioblastoma (GBM) is one of the most aggressive forms of brain cancer that presents with a median survival rate of 14-30 months and along with a discouraging five-year survival rate of 4-5%. Standard treatment of newly diagnosed GBM, also known as the Stupp protocol, includes a maximally safe surgical resection followed by radiation and chemotherapy. Despite these treatment regimens, recurrence is almost inevitable, emphasizing the need for new therapies to combat the aggressive nature of GBMs. Tumor Treating Fields (TTFs) are a relatively new application to the treatment of GBMs, and results have been promising with both progression-free survival and overall survival when TTFs have been used in combination with temozolomide. This article critically reviews the biophysical and biological mechanisms of TTFs, their clinical efficacy, and discusses the results in clinical trials, including EF-11 and EF-14. Both trials have demonstrated that TTFs can enhance progression free survival and overall survival without compromising quality of life or causing severe adverse effects. Despite the high cost associated with TTFs and the need for further analysis to determine the most effective ways to integrate TTFs into GBM treatments, TTFs represent a significant advancement in GBM therapy and offer hope for improved patient prognosis.</p>","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"8 3","pages":"265-270"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Carvajal, D. Ballen, Natallie Jurado,, Rafael Beltrán, M. Alarcón, Camilo Vallejo-Yepes, Marcela Núñez, R. Parra, Ricardo Brugés-Maya
{"title":"Small-Cell Lung Cancer in a Cancer Center in Colombia","authors":"C. Carvajal, D. Ballen, Natallie Jurado,, Rafael Beltrán, M. Alarcón, Camilo Vallejo-Yepes, Marcela Núñez, R. Parra, Ricardo Brugés-Maya","doi":"10.26502/jcsct.5079186","DOIUrl":"https://doi.org/10.26502/jcsct.5079186","url":null,"abstract":"","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Alfraih, Mostafa F. Mohammed Saleh, A. Abdrabou, A. Haroon, K. AlSaleh, T. Owaidah
{"title":"Different Coagulation Markers as Predictors of Severity in Cancer Patients with COVID-19 Infection","authors":"F. Alfraih, Mostafa F. Mohammed Saleh, A. Abdrabou, A. Haroon, K. AlSaleh, T. Owaidah","doi":"10.26502/jcsct.5079194","DOIUrl":"https://doi.org/10.26502/jcsct.5079194","url":null,"abstract":"","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Albarrán, M. Villamayor, Ignacio Ruz, Jesús Chamorro, D. Rosero, J. Pozas, María San Román, P. A. Ballesteros, María Ángeles Vaz
{"title":"Spinal Intramedullary Ewing Sarcoma with Meningeal Carcinomatosis: A Complete Response to Chemotherapy and Neuroaxis Irradiation. Case Report and Review of Literature","authors":"V. Albarrán, M. Villamayor, Ignacio Ruz, Jesús Chamorro, D. Rosero, J. Pozas, María San Román, P. A. Ballesteros, María Ángeles Vaz","doi":"10.26502/jcsct.5079195","DOIUrl":"https://doi.org/10.26502/jcsct.5079195","url":null,"abstract":"","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Almost 25,000 new cases of epithelial ovarian cancer (EOC) are reported each year in the United States. Cancers of the ovary have poor prognosis due to drug resistance and metastasis, and have the highest mortality rate of all the known gynecological malignancies. Despite concerted efforts to develop new strategies for preventing and treating ovarian cancer, novel and more effective non-toxic therapies for ovarian cancer are urgently needed. Recent observations show that RO 48-8071 ([4’-[6-(Allylmethylamino)hexyloxy]-4-bromo-2’-fluorobenzophenone fumarate] [RO], a small-molecule inhibitor of the key cholesterol biosynthesis enzyme 2, 3-oxidosqualene cyclase, inhibits breast and prostate cancer cells. RO also induces the tumor-suppressor protein estrogen receptor (ER) β in both breast- and prostate-cancer cells, and also inhibits growth of ovarian-cancer cells both in vitro and in vivo. Extending upon these earlier studies, here we found that RO also induces ERβ expression in OVCAR-3 ovarian-cancer cells. Further, we demonstrated that treatment of two ovarian-cancer cell lines (OVCAR-3 and SK-OV-3) with liquiritigenin (LQ), a naturally occurring compound that is an ERβ agonist, reduced cell viability in vitro. When we treated OVCAR-3 and SK-OV-3 cells with RO, LQ, or RO + LQ, we observed that RO + LQ combination treatment synergistically reduced cell viability. Further in vivo studies examining the effects of RO + LQ combination treatment on EOC are warranted, as a means of exploring a potential new therapeutic approach to combat ovarian cancers with minimal toxicity.
{"title":"Liquiritigenin Enhances the Inhibitory Effects of the Cholesterol Biosynthesis Inhibitor RO 48-8071 on Cell Viability in Ovarian-Cancer Cells in Vitro","authors":"Yayun Liang, Salman M Hyder","doi":"10.26502/jcsct.5079207","DOIUrl":"https://doi.org/10.26502/jcsct.5079207","url":null,"abstract":"Almost 25,000 new cases of epithelial ovarian cancer (EOC) are reported each year in the United States. Cancers of the ovary have poor prognosis due to drug resistance and metastasis, and have the highest mortality rate of all the known gynecological malignancies. Despite concerted efforts to develop new strategies for preventing and treating ovarian cancer, novel and more effective non-toxic therapies for ovarian cancer are urgently needed. Recent observations show that RO 48-8071 ([4’-[6-(Allylmethylamino)hexyloxy]-4-bromo-2’-fluorobenzophenone fumarate] [RO], a small-molecule inhibitor of the key cholesterol biosynthesis enzyme 2, 3-oxidosqualene cyclase, inhibits breast and prostate cancer cells. RO also induces the tumor-suppressor protein estrogen receptor (ER) β in both breast- and prostate-cancer cells, and also inhibits growth of ovarian-cancer cells both in vitro and in vivo. Extending upon these earlier studies, here we found that RO also induces ERβ expression in OVCAR-3 ovarian-cancer cells. Further, we demonstrated that treatment of two ovarian-cancer cell lines (OVCAR-3 and SK-OV-3) with liquiritigenin (LQ), a naturally occurring compound that is an ERβ agonist, reduced cell viability in vitro. When we treated OVCAR-3 and SK-OV-3 cells with RO, LQ, or RO + LQ, we observed that RO + LQ combination treatment synergistically reduced cell viability. Further in vivo studies examining the effects of RO + LQ combination treatment on EOC are warranted, as a means of exploring a potential new therapeutic approach to combat ovarian cancers with minimal toxicity.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135838181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Burkan Nasr, Anwar Al_junaeed, Ghaleb Al Sady, Ahmad Al Shehari, A. Amri, M. Issa, Abdulhakim Al Tamimi, Saeed Al Bahlooli, Mohammed Al_Sormi, Abdulfattah Altam, Yasser A Obadiel, M. Al-Shehari, Ali Hiddan.
{"title":"Lung Hydatid Cysts in Children, Evaluation and Surgical Management","authors":"Burkan Nasr, Anwar Al_junaeed, Ghaleb Al Sady, Ahmad Al Shehari, A. Amri, M. Issa, Abdulhakim Al Tamimi, Saeed Al Bahlooli, Mohammed Al_Sormi, Abdulfattah Altam, Yasser A Obadiel, M. Al-Shehari, Ali Hiddan.","doi":"10.26502/jcsct.5079189","DOIUrl":"https://doi.org/10.26502/jcsct.5079189","url":null,"abstract":"","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reviewing Stereotactic Body Radiation Therapy Boost after Neoadjuvant Chemoradiation as an Alternative to Brachytherapy Boost for Locally Advanced Cervical Cancer","authors":"","doi":"10.26502/jcsct.5079196","DOIUrl":"https://doi.org/10.26502/jcsct.5079196","url":null,"abstract":"","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Hassan, A. Allam, Saad Jobran Eziada, Hiba Elathir, Azar Saleeml, Sair Ibrahim, Zeinab Idris, Shaikhah Mohsen
{"title":"The Experience of Palliative Care Patients Who Underwent Telemedicine in the State of Qatar during the COVID-19 Pandemic","authors":"A. Hassan, A. Allam, Saad Jobran Eziada, Hiba Elathir, Azar Saleeml, Sair Ibrahim, Zeinab Idris, Shaikhah Mohsen","doi":"10.26502/jcsct.5079201","DOIUrl":"https://doi.org/10.26502/jcsct.5079201","url":null,"abstract":"","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Krishnasri Padamandala, Santosh G. Honavar, Rolika Bansal, Surya Durga Prasad M, Padmaja Gadiraju, Geeta K Vemuganti
{"title":"Investigating the Quality of Life of Retinoblastoma Survivors: An Initial Exploration","authors":"Krishnasri Padamandala, Santosh G. Honavar, Rolika Bansal, Surya Durga Prasad M, Padmaja Gadiraju, Geeta K Vemuganti","doi":"10.26502/jcsct.5079202","DOIUrl":"https://doi.org/10.26502/jcsct.5079202","url":null,"abstract":"","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号